HER2 NSCLC

Nov 13, 2026

Summary HER2 mutations are detected in approximately 1–5% of NSCLC patients, although the actual prevalence may be underestimated due to limited next-generation sequencing (NGS) adoption, particularly in community settings, where testing rates remain below 50%. The approval of AstraZeneca and Daiichi Sankyo’...

May 15, 2026

Summary NSCLC accounts for nearly 80–85% of all lung cancer cases. Among these patients, HER2 mutations are identified in roughly 1–4% of cases.  ENHERTU became the first FDA-approved therapy for unresectable/metastatic HER2 (ERBB2)-mutant NSCLC in 2022; however, along with recently approved HERNEXEOS and HY...